Regenerative Medicines for Remyelination: From Aspiration to Reality.
Stimulating an endogenous regenerative response is a powerful approach for potential treatment of chronic demyelinating diseases such as multiple sclerosis. Recently in Nature, Najm et al. (2015) identified two clinically relevant, FDA-approved compounds that promote oligodendrocyte progenitor cell differentiation and induce remyelination in demyelinating disease models.